UBS Group
BMGL

UBS Group’s Basel Medical BMGL Stock Holding History

UBS Group’s Portfolio BMGL Stock Details BMGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.7K Buy
1,088
+414
+61% +$3.27K ﹤0.01% 8559
2025
Q4 		$3.96K Buy
674
+182
+37% +$2.69K ﹤0.01% 8912
2025
Q3 		$10.7K Buy
492
+22
+5% +$552 ﹤0.01% 8520
2025
Q2 		$10K Buy
+470
New +$20.7K ﹤0.01% 8863

Other funds holding BMGL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM

UBS Group's BMGL Position: Q1 2026 in Review

UBS Group increased its Basel Medical (BMGL) stake by 61% in Q1 2026, buying an estimated $3.27K and bringing the position to 1,088 shares worth $7.7K. The position accounts for ﹤0.01% of the portfolio, ranked #8559.

UBS Group first reported a position in BMGL in Q2 2025 and has held it in 4 quarters since. The position peaked at $10.7K in Q3 2025. 4 funds tracked by Wall St. Rank hold BMGL as of Q1 2026.

  • UBS Group held 1,088 shares of Basel Medical worth $7.7K as of Q1 2026.
  • UBS Group bought 414 Basel Medical shares in Q1 2026, an estimated $3.27K.
  • Basel Medical made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8559 holding.
  • UBS Group first reported a position in Basel Medical in Q2 2025 and has held it in 4 quarters since.
  • UBS Group's Basel Medical position peaked at $10.7K in Q3 2025.
  • 4 funds tracked by Wall St. Rank held Basel Medical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.